Status: Recruiting
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \>/= 65 years with hematologic malignancies.
Participants needed: 26
Trial details
Phase: Phase 1Age: 65+Biological sex: AllType: InterventionalSponsor: Ronald PaquetteUpdated: May 7, 2026Locations: 1
Eligibility criteria
Patient age >/= 65 years [+4]
Patient has a diagnosis of myelofibrosis [+6]